Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials

Gastroenterology

Volumn 117, Issue 2, 1999, Pages 408-413

  Schalm, S W ^a   Weiland, O ^a   Hansen, B E ^a   Milella, M ^a   Lai, M Y ^a   Hollander, A ^a   Michielsen, P P ^a   Bellobuono, A ^a   Chemello, L ^a   Pastore, G ^a   Chen, D S ^a   Brouwer, J T ^a   Braconnier, J H ^a   Fryden, A ^a   Norkrans, G ^a   Reichard, O ^a   Adler, M ^a   Chamuleau, R A F M ^a   Delwaide, J ^a   Elewaut, A ^a   Fevery, J ^a   Hautekeete, M L ^a   Nevens, F ^a   Den Ouden Muller, J W ^a   Wismans, P J ^a   Casalino, C ^a   Maselli, R ^a   Pietromatera, G ^a   Chan, K W ^a   Kao, J H ^a   Ideo, G ^a   Alberti, A ^a   Cavalletto, L ^a   Boot, J ^a   Van Vliet, C ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0032801727     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.1999.0029900408     Document Type: Article

References (16)

1. Anonymous National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C Hepatology 26 suppl 1 1997 2S 10S
2. JT Brouwer F Nevens B Kleter A Elewaut M Adler R Brenard RAFM Chamuleau PP Michielsen J Pirotte ML Hautekeete J Weber N Bourgeois BE Hansen CM Bronkhorst RA Heijtink J Fevery SW Schalm Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients J Hepatol 28 1998 951 959
3. EB Keefe FB Hollinger the Consensus Interferon Study Group Therapy of hepatitis C: consensus interferon trials Hepatology 26 suppl 1 1997 101S 107S
4. S.W. Schalm G. Fattovich J.T. Brouwer Therapy of hepatitis C: patients with cirrhosis Hepatology 26 suppl 1 1997 128S 132S
5. J.T. Brouwer F. Nevens P. Michielsen M.L. Hautekeete R.A.F. Chamuleau M. Adler J. Delwaide R.A. Heijtink S.W. Schalm What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre trial on ribavirin monotherapy versus prolonged combination with Interferon J Hepatol 21 1994 S17
6. L. Chemello L. Cavaletto E. Bernardinello M. Guido P. Pontisso A. Alberti The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C J Hepatol 23 suppl 2 1995 8 12
7. M.Y. Lai J.H. Kao P.M. Yang J.T. Wang P.J. Chen K.W. Chan J.S. Chu D.S. Chen Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C Gastroenterology 111 1996 1307 1312
8. A. Bellobuono L. Mondazzi S. Tempini E. Silini F. Vicari G. Ideo Ribavirin and lymphblastoid α-interferon vs α-interferon alone in the retreatment of chronic hepatitis C: a randomized clinical trial J Viral Hepat 4 1997 185 191
9. O. Reichard G. Norkrans A. Fr yden J.-H. Braconier A. Sönnerborg O. Weiland Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C Lancet 351 1998 83 87
10. Milella M, Santantonio T, Pietromatera G, Maselli R, Casalino C, Appice A, Mariano N, Genchi C, Pastore G. Ribavirin plus IFN vs IFN alone in the treatment of either non-responder or relapser patients with chronic hepatitis C. International Viral Hepatitis and Liver Disease Symposium, Rome, 1996.
11. S.W. Schalm B.E. Hansen L. Chemello A. Bellobuono J.T. Brouwer O. Weiland L. Cavalletto R. Schvarcz G. Ideo A. Alberti Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centres J Hepatol 26 1997 961 966
12. D.W. Hosmer S. Lemeshow Applied logistic regression 1st ed 1989 Wiley New York
13. T. Poynard P. Marcellin S.S. Lee C. Niederau G.S. Minuk G. Ideo V. Bain J. Heathcote S. Zeuzem C. Trepo J. Albrecht Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1432 1462
14. J.G. Mchutchison S.C. Gordon E.R. Schiff M.L. Shiffman W.M. Lee V.K. Rustgi Z.D. Goodman M.-H. Ling S. Cort J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
15. G.L. Davis R. Esteban-Mur V.K. Rustgi J. Hoefs S.C. Gordon C. Trepo M.L. Shiffman S. Zeuzem A. Craxi M.-H. Ling J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N Engl J Med 339 1998 1493 1499
16. J. Lau J.P.A. Ioannidis C.H. Schmid Meta-analysis duet. Summing up evidence: one answer is not always enough Lancet 351 1998 123 127